Nutranomics, Inc. (NNRX)
Today, NNRX surged (+6.25%) up +0.025 at $.425 with 338,207 shares in play thus far (ref. google finance Delayed: 2:07PM EDT October 9, 2013).
Nutranomics, Inc. previously reported the results of human patient clinical studies undertaken by the Company regarding Glucozyme™ are nearing a public release date. Glucozyme™ is a proprietary nutritional supplement being developed by Nutranomics that has been shown to aid in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes.
Following the conclusion of the latest Glucozyme clinical studies conducted in Japan and Mexico, the resulting new patient data was compiled and compared with previous testing conducted in North America prior to submission for product approval and distribution in several world markets.
Nutranomics, Inc. (NNRX) 5 day chart:
No comments:
Post a Comment